Clinical Trials Logo

Filter by:
NCT ID: NCT00460551 Terminated - Clinical trials for Non Small Cell Lung Cancer

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.

NCT ID: NCT00452478 Terminated - Kidney Diseases Clinical Trials

Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5

Start date: May 22, 2007
Phase: Phase 4
Study type: Interventional

The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to patients on haemodialysis works as well as other treatments currently used to lower blood phosphorus levels.

NCT ID: NCT00452166 Terminated - Insulin Resistance Clinical Trials

Rosiglitazone and Insulin Resistance in Renally Impaired Patients

Start date: April 2007
Phase: Phase 3
Study type: Interventional

30 non-diabetic, non-obese patients with stage 4 chronic kidney disease will be asked to participate in this metabolic study. The primary aim of this study is to determine the effect of rosiglitazone on insulin resistance in non-obese patients with non-diabetic stage 4 CKD. Secondary end points are the effects on inflammation (hsCRP), lipid profile, bone density and body composition.

NCT ID: NCT00449813 Terminated - Clinical trials for Gastroesophageal Reflux Disease

The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Start date: March 2007
Phase: Phase 4
Study type: Interventional

The aim of the study is to compare two different endpoint measures: heartburn as assessed by the physicians versus gastroesophageal reflux disease (GERD)-related symptoms as assessed by the patient using the ReQuestâ„¢ questionnaire. The assessment is made in GERD-patients treated with a daily dose of 40 mg oral pantoprazole over an 8-week period.

NCT ID: NCT00448266 Terminated - Breast Cancer Clinical Trials

Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

Start date: May 2007
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial will investigate the ability of chemotherapy with 'Intensified Aklylating Agents (IAA) to achieve a high pathological complete response (pCR) rate when employed in the preoperative chemotherapy of breast cancer with evidence of a Homologous Recomination Deficiency (HRD).

NCT ID: NCT00447421 Terminated - Clinical trials for Small Cell Lung Cancer

A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

Start date: February 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.

NCT ID: NCT00444639 Terminated - Prostate Cancer Clinical Trials

Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

Start date: February 2007
Phase: Phase 2
Study type: Interventional

The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH). GnRH is a hormone secreted by hypothalamus (a gland located in brain) and controls the production of sex hormones (eg testosterone in men) in other organs in the body. The growth of prostate cancer cells, one of the most common cancers in men, is induced by the hormone testosterone. Hormonotherapy is one of treatments available to treat this type of disease by controlling the testosterone serum level. Pamorelin® 11,25 mg is normally injected in the muscle but this type of injection is not suitable for every patient. Therefore the primary purpose of this study is to assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via standard intramuscular (IM) injection based on the percentage of patients presenting a testosterone level ≤ 50 ng/dl at week 24.

NCT ID: NCT00433017 Terminated - Clinical trials for Macular Degeneration

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Start date: May 2007
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration

NCT ID: NCT00430716 Terminated - Clinical trials for Pulmonary Arterial Hypertension

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

Start date: April 8, 2008
Phase: Phase 4
Study type: Interventional

To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.

NCT ID: NCT00430300 Terminated - Clinical trials for Pulmonary Disease, Chronic Obstructive

Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.

Start date: January 2007
Phase: Phase 2
Study type: Interventional

Safety and efficacy (measured by spirometry) of UK-432,097 administration will be tested in patients with chronic obstructive pulmonary disease.